<DOC>
	<DOCNO>NCT02888522</DOCNO>
	<brief_summary>Allogeneic hematopoietic stem cell transplantation ( Allo-HSCT ) effective treatment Acute Myeloid Leukemia ( AML ) . After allo-HSCT , relapse major cause mortality occur 30 % case . The occurrence relapse important first three month post-allogeneic transplant , gradually decrease first year post-allograft become weak . After relapse , therapeutic option include reduction immunosuppression , administration donor lymphocyte ( DLI ) , chemotherapy new transplant . The performance influence early introduction treatment whose effectiveness relate importance tumor burden . Immunomodulation preemptive strategy recently establish decrease immunosuppression achieve DLIs patient high risk relapse , occurrence relapse . The aim study evaluate incidence relapse follow recommendation post-allogeneic transplant immunomodulation French society bone marrow transplantation .</brief_summary>
	<brief_title>Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation AML</brief_title>
	<detailed_description />
	<criteria>Acute myeloid leukemia Allogeneic stem cell transplantation ( relate unrelated ) Age 18 year Cord blood transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>